VIVUS was incorporated in 1991 as a California corporation and reincorporated in 1996 as a Delaware corporation. The Company is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes. Its FDA- approved therapies includes, Qsymia and STENDRA. Its drug Qsymia (phentermine and topiramate extended-release) was approved by the FDA, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Its drug STENDRA, or avanafil, is an oral phosphodiesterase type 5, or PDE5, inhibitor that have licensed from Mitsubishi Tanabe Pharma Corporation. STENDRA was approved by the FDA, for the treatment of erectile dysfunction, or ED, in the United States. Outside the United States, the Company sells products principally in the EU. The Company relies on PDI, Inc., or PDI, a third-party contract sales organization, to assist with the hiring of sales representatives and the promotion of Qsymia to physicians. The Company hold various patents and patent applications in the U.S. and abroad targeting obesity and morbidities related to obesity, including sleep apnea and diabetes, and sexual health, among other. The Company's prescription pharmaceutical products are subject to extensive pre- and post-marketing regulation by the FDA.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.